Pyxis Announces Pricing of Upsized Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
IPO for Pyxis Oncology (PYXS) Upsized IPO Opens 19% Higher, Valuing Co. at ~$580M
October 8, 2021 11:06 AM EDTToday's IPO for Pyxis Oncology, Inc. (Nasdaq: PYXS) opened for trading at $19 after pricing 10,500,000 shares of common stock at an initial public offering price of $16.00 per share, the high end of the range. The IPO size was raised from 9,500,000 shares and prior to that from 8,340,000... More
